Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine efficacy and toxicity of recombinant human
epidermal growth factor (rhEGF) as a preventive drug of oral mucositis during intensive
chemotherapy with stem cell transplantation in patients with hematologic malignancies.